- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00785200
MRSA Colonization and Control in the Dallas County Jail
June 11, 2013 updated by: University of Chicago
The goal of this 3-year project is to control the spread of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in the Dallas County Jail.
CA-MRSA is a bacterium spreading rapidly through healthy populations and becoming an epidemic in many regions of the U.S.
Many people in the community are asymptomatically colonized by MRSA.
There have been outbreaks of MRSA infections at prisons and jails.
We will study the spread of MRSA in the jail to better understand how the bacteria are transmitted from person to person there and how we can prevent their transmission.
All detainees asked to participate must give informed consent to do so; their privacy will be carefully protected.
Detainees with a history of allergy to CHG will be excluded.
Seventeen objects in the jail will be sampled for contamination with MRSA.
Bacteria will be collected from all cultures obtained from patients with bacterial skin infections for 18 months in a part of the jail in order to determine how frequently these infections are caused by MRSA relative to other bacteria.
A group of about 1500 adult detainees will be tested for colonization with MRSA in order to determine how commonly detainees carry the bacterium.
A cluster-randomized 6-month study will be undertaken among these detainees and those who take their places when they leave the jail to determine if chlorhexidine (CHG)-containing disposable wash cloths for skin cleaning can decrease the prevalence of MRSA skin or nose colonization.
Detainees receiving CHG cloths (about 500 detainees) will be compared to detainees receiving water-soaked cloths for skin cleaning (about 500 detainees) or no intervention (about 500 detainees).
The primary outcome will be a difference in average colonization prevalence in detention tanks, which are discrete detention units housing detainees, comparing the usual care to the CHG-exposed tanks after 6 months of CHG cloth use.
A secondary outcome will be a decrease in skin infections from any cause in the tanks receiving CHG compared with usual care.
All of the MRSA isolates and a sample of the S. aureus isolates susceptible to methicillin from specimens colonizing or infecting detainees, as well as those contaminating surfaces and objects in the jail will be tested genetically in order to determine which strains of MRSA are present in the jail.
This study may identify ways to stop the spread of MRSA among people in jails and prisons, as well as other places.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4194
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- The Dallas County Jail
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Admission to a participating tank in the jail
Exclusion Criteria:
- History of hypersensitivity reaction to chlorhexidine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chlorhexidine
Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months.
Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
|
Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
|
Placebo Comparator: Water
Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period.
If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
|
Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
|
No Intervention: Usual care
Approximately 500 detainees in approximately 23 detention tanks will be enrolled.
These detainees will not receive any intervention.
They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average prevalence of MRSA hand or nasal colonization in study tanks (i.e., 24-60-person detention divisions) receiving CHG cloths vs. usual care
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average incidence of skin and soft tissue infections requiring incision and drainage per tank in a 6 month period, comparing group of study tanks receiving CHG-soaked washcloths to those receiving usual care.
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert S Daum, MD, University of Chicago
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
July 1, 2009
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
November 3, 2008
First Submitted That Met QC Criteria
November 4, 2008
First Posted (Estimate)
November 5, 2008
Study Record Updates
Last Update Posted (Estimate)
June 12, 2013
Last Update Submitted That Met QC Criteria
June 11, 2013
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Infections
- Communicable Diseases
- Skin Diseases, Infectious
- Soft Tissue Infections
- Skin Diseases
- Staphylococcal Infections
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Disinfectants
- Chlorhexidine
Other Study ID Numbers
- 14633A (R01 CI000373-03)
- R01CI000373-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Diseases, Infectious
-
Paratek Pharmaceuticals IncCompletedInfectious Skin Disease | Bacterial Skin DiseaseUnited States
-
PfizerCompletedIntra-Abdominal Infections | Skin Disease, Infectious
-
Johns Hopkins Bloomberg School of Public HealthCompleted
-
Center for Innovation and Research OrganizationCompleted
-
Cubist Pharmaceuticals LLCCompletedSkin Diseases, InfectiousUnited States, India, Panama
-
Christiana Care Health ServicesCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...PriCara, Unit of Ortho-McNeil, Inc.Completed
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedSkin Diseases, InfectiousTaiwan
-
BayerTerminatedSkin Disease, InfectiousRussian Federation, Mexico, Singapore
Clinical Trials on Chlorhexidine
-
University of OsloUnknown
-
Universidade do Vale do SapucaiCompleted
-
University of OsloGöteborg UniversityCompletedDental Caries | Periodontal Disease
-
University of MilanCompleted
-
University of TorontoUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Unity... and other collaboratorsCompletedMortality | Oral Health | Pain, Orofacial | Dryness, MouthCanada
-
Liaquat National Hospital & Medical CollegeLiaquat College of Medicine and DentostryCompleted
-
University of BaghdadCompletedImpacted Third Molar ToothIraq
-
Virginia Commonwealth UniversityNational Institute of Nursing Research (NINR)Completed
-
Mahidol UniversityCompletedAntibiotic Resistant InfectionThailand
-
Damascus UniversityCompletedDental Caries | Infection, Bacterial | Tooth, DeciduousSyrian Arab Republic